Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Bgt-226 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 13/20 | 1.00 |
| ▸ | PIK3CA known ✓ | P42336 | 3/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | MELK | Q14680 | 1/20 | 1.00 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | TP53RK | Q96S44 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.90 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.90 |
| ▸ | RIOK2 | Q9BVS4 | 7/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ATR | Q13535 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bgt-226 Free Base SCHEMBL29351405 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL146939 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29388241 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL31326455 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29394351 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL996047 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL996046 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| SCHEMBL24455231 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| SCHEMBL20548306 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| SCHEMBL928275 | 0.92 | MTOR (0.86) | MTORPIK3CAPIK3CDCSNK2A2FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | NOVARTIS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12454564-B2 | Compositions and methods for T cell engineering | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2025-10-28 | — | — | US | disclosed |
| CN-114395624-A | Methods for treatment and diagnosis of cancer | 基因泰克公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114381521-A | Methods and biomarkers for efficacy prediction and assessment of OX40 agonist treatment | 豪夫迈·罗氏有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114302746-A | Combination therapy comprising an anti-CD 25 antibody drug conjugate and another agent | ADC治疗有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | MTOR 2736/4885PIK3CA 3161/4885PIK3CD 3063/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | MTOR 4538/4885PIK3CA 2438/4885PIK3CD 2996/4885 |
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | EZH2, BMI1, SUZ12 | MTOR 572/4885PIK3CA 1904/4885PIK3CD 1648/4885 |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | EZH2, NR3C1, SUZ12 | MTOR 2060/4885PIK3CA 2356/4885PIK3CD 2225/4885 |
| US-12454564-B2 | Compositions and methods for T cell engineering | PBK, CD47, MICA | MTOR 3633/4885PIK3CA 1567/4885PIK3CD 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.